rTMS for depression
Repetitive transcranial magnetic stimulation (rTMS) uses short magnetic pulses to activate nerve cells in the left dorsolateral prefrontal cortex – a region whose activity is altered in depression. No anaesthesia and no medication are involved; you sit awake in a treatment chair.
We provide rTMS as neurological co-treatment, coordinated with your psychiatrist, psychotherapist or GP, whose care continues. Whether rTMS is an option for you is decided in a detailed consultation with a neurological examination.
Who rTMS may be suitable for
- A depressive episode in which one or more antidepressants have not worked sufficiently or were not tolerated
- A wish for a non-drug addition to ongoing treatment
- A medical diagnosis exists or is established together with your treating clinicians
What we do
| Consultation | Neurological examination, check of indication and exclusion criteria, coordination with your treating clinicians, informed consent and a written cost estimate. |
|---|---|
| Protocol | High-frequency rTMS (10 Hz) or intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex; the target is determined individually (motor threshold, navigation). |
| Course | Usually 20 to 30 sessions on five days a week over four to six weeks. Depending on the protocol a session involves 3 to 20 minutes of stimulation, about 30 minutes including preparation. |
| Follow-up | Standardised outcome measures (e.g. PHQ-9, PROMIS Depression) before, during and after the course; a summary report to your treating practice if you wish. |
What the evidence says
The European expert group led by Lefaucheur (Clinical Neurophysiology 2020) rates high-frequency rTMS of the left dorsolateral prefrontal cortex in depression as level A evidence (“definite efficacy”); a large head-to-head trial (Blumberger 2018) found iTBS to be equivalent. The German S3 guideline on unipolar depression lists rTMS as an option when medication has not worked sufficiently.
In controlled trials, roughly 40 to 50 percent of people with treatment-resistant depression respond to a course and about 25 to 30 percent reach remission. These are group results; an individual outcome cannot be guaranteed.
Procedure, duration, costs
Limits and safety
rTMS is not possible with metallic or electronic implants in the head (e.g. cochlear implant, deep brain stimulator) and is used only after careful consideration in people with pacemakers, epilepsy or an increased seizure risk. The most common side effects are transient headache and scalp discomfort; a seizure is very rare (below 0.1 percent per course).
Outpatient rTMS is not the right setting in an acute crisis. In that case please contact the Berlin crisis service (030 390 63 00, around the clock) or, in immediate danger, the emergency number 112.
Book a consultation +49 30 75633615
Related topics
This page provides general information and does not replace medical advice or an examination. Last updated: October 2026.
Next: rTMS for chronic pain